[Skip to Content]
[Skip to Content Landing]
Views 394
Citations 0
Clinical Trials Update
May 26, 2015

Genotype Doesn’t Affect Response to Naltrexone for Alcohol Dependence

JAMA. 2015;313(20):2015. doi:10.1001/jama.2015.5173

A genetic variation of the µ-opioid receptor did not predict response to naltrexone for the treatment of alcohol dependence, found a randomized trial including 221 alcohol-dependent people who were stratified by genotype. Based on previous preclinical research and encouraging clinical trial data, the researchers had hypothesized that the single-nucleotide polymorphism of the µ-opioid receptor gene (A+118G, Asn40Asp) would moderate response to naltrexone treatment (Oslin DW et al. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2014.3053 [published online March 11, 2015]). Participants were randomly assigned to receive once-daily naltrexone treatment or placebo based on the presence of 1 or 2 copies of the Asp40 allele compared with those homozygous for the Asn40 allele in the 12-week trial. The researchers found that genotype had no effect on whether participants relapsed to heavy drinking after naltrexone treatment.